单纯疱疹病毒个案数目增加，以推动全球的单纯疱疹病毒治疗市场，根据一个新的全球工业分析公司的报告
GIA announces the release of a comprehensive global report on herpes simplex virus treatment markets.
GIA的宣布释放了一个全面的单纯疱疹病毒治疗市场上的全球报告。
The global market for herpes simplex virus treatment is forecast to reach $4.9 billion by the year 2017.
为单纯疱疹病毒治疗的全球市场预计将达到2017年的49亿美元。
Principal growth drivers include increasing number of people affected by herpes simplex virus (HSV) infection, need for innovative therapies, search for novel antiviral drugs, increased research on HSV vaccines and growing popularity of Nanoviricides
主要增长动力包括单纯疱疹病毒（HSV）感染所影响的人越来越多，需要创新疗法，寻找新的抗病毒药物，增加对单纯疱疹病毒疫苗的研究，越来越多的Nanoviricides普及
- [url=]
[/url] [url=]
[/url] [url=]
[/url] [url=]
[/url] 
Herpes Simplex Virus Treatment: A Global Strategic Business Report
单纯疱疹病毒治疗：全球战略商业报告“
San Jose, California (PRWEB) April 23, 2012
加利福尼亚州圣何塞市（华美），2012年4月23日
Follow us on LinkedIn – Genital herpes is one of the most common sexually transmitted diseases in the US.
我们在LinkedIn -生殖器疱疹是性病最常见的疾病，在美国之一。
The prevalence of genital herpes is estimated at 63 million in the US alone, with about 500,000 to 1,000,000 new cases being diagnosed every year.
生殖器疱疹的患病率估计在63万，仅在美国，被确诊，每年约有50万至100万新病例。
According to the Centers for Disease Control and Prevention, the rate of infection of genital herpes has increased by about 30% between the late 1970s and the early 1990s.
据美国疾病控制和预防中心，生殖器疱疹的传染率增加了30％左右，20世纪70年代末和90年代初之间。
However, since more than 80% of people with genital herpes do not have an idea that they are infected, resulting in low diagnosis rate, there exists significant growth potential for Herpes Simplex Virus (HSV) treatment drugs.
然而，因为超过80％的人患有生殖器疱疹的不有，他们被感染的想法，导致低诊断率，存在显着的增长潜力
单纯疱疹病毒 （HSV）的治疗药物。
In addition, the lack of availability of drugs for the complete curing of HSV also bodes well for the development of new drugs.
此外，完全固化的单纯疱疹病毒药品供应的缺乏也预示着开发新的药物。
The HSV market presently includes various anti-viral therapies that alleviate painful symptoms of the infection.
单纯疱疹病毒市场目前包括各种抗病毒治疗，缓解疼痛症状的感染。
However, these drugs are known to cause drug related toxicity as a result of their interference with the natural metabolism of the human body.
然而，这些药物被称为作为其与人体的自然代谢的干扰而导致药物相关毒性。
The availability of safer drugs, therefore, is a primary requirement for the therapeutics market.
提供更安全的药物，因此，是一种疗法市场的主要要求。
In addition, with the virus subsequently developing resistance against the existing batch of anti-virals, the need for innovative therapies for the treatment of herpes simplex infection, and the search for novel antiviral drugs continues.
此外，继续与病毒的随后发展对现有的抗病毒药物一批，需要创新疗法治疗单纯疱疹病毒感染，并寻找新的抗病毒药物耐药。
This presents a huge potential for the growth of herpes simplex therapeutics market in future.
这提出了一个单纯疱疹疗法市场在未来的增长潜力巨大。
The US represents the largest regional market for Herpes Simplex Virus (HSV) treatment worldwide, as stated by the new market research report on Herpes Simplex Virus Treatment .
美国代表单纯疱疹病毒（HSV）治疗全球新的市场研究报告指出，最大的区域市场，
单纯疱疹病毒治疗 。
However, growth in the market is expected to emanate mainly from the developing markets and other regions.
然而，在市场的增长预计将主要源自发展中市场和其他地区。
Rest of World is projected to post a compounded annual growth rate of close to 7% during the analysis period 2009-2107.
世界其他地区预计将在分析期间二〇〇九年至2107年的发表的复合年均增长率接近7％。
Herpes therapeutics market is considerably genericized.
大大genericized疱疹疗法市场。
One of the key factors hampering prospects for new drugs is the generic incursion in the market, which led to the entry of several generic variants and reduced prices of the drugs in the market.
阻碍新的药物前景的关键因素之一，是在市场上通用的入侵，而导致几种通用的变种和降价的药品在市场上的条目。
However, the market is expected to post strong growth, owing to continuing rise in the incidence of herpes simplex virus infection.
然而，市场有望强劲增长，由于在单纯疱疹病毒感染的发病率持续上升。
A strong pipeline of vaccines for the prevention and treatment of HSV2 constitutes another growth driver.
HSV2预防和治疗疫苗的一个强大的管道构成另一增长动力。
Although the market presently awaits the commercial launch of the first such HSV vaccine , there are about eleven vaccines, including prophylactic, therapeutic and a combination of both, currently under development at various stages of development.
虽然目前市场等待
单纯疱疹病毒疫苗的首次商业发射，还有约11个疫苗，包括预防，治疗和两者的结合，目前正在开发中，处于不同的发展阶段。
Besides, another promising area in the HSV treatment includes the emergence of Nanoviricides drugs, which are expected to provide increased opportunities owing to their distinct mechanism of action in comparison to the existing drugs.
此外，还有在单纯疱疹病毒治疗的有前途的领域包括Nanoviricides药物，这是由于他们的行动不同的机制在现有药物相比，预计将提供更多的机会出现。
Major players profiled in the report include Agenus Inc., AiCuris GmbH & Co.KG, Astellas Pharma Inc., Clinigen Group, Cytogenix Inc., Genocea Biosciences, GlaxoSmithKline Plc., Lumavita AG, NanoBio Corporation, NanoViricides Inc., Novartis International AG, Sanofi, Starpharma Holdings Limited, Vical, Genocea Biosciences, among others.
该报告在主要厂商包括，AiCuris GmbH＆Co.KG公司Agenus公司，阿斯特拉制药公司，Clinigen集团，Cytogenix公司，Genocea Biosciences公司，葛兰素史克。，Lumavita公司，NanoBio公司，NanoViricides公司，诺华国际公司，赛诺菲Starpharma控股有限公司，维考，Genocea Biosciences公司，其中包括。
The research report titled “Herpes Simplex Virus Treatment: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the Herpes Simplex Virus treatment, current market trends, key growth drivers, the available treatment, overview of major drugs, insight into current leading and pipeline drugs, recent product approvals, recent industry activity, and profiles of major/niche global as well as regional market participants.
该研究报告题为“单纯疱疹病毒治疗：全球战略商业报告”公布的全球工业分析公司，提供全面检讨单纯的疱疹病毒治疗，目前的市场趋势，主要增长动力，可供选择的治疗，主要概述药物，深入了解当前的领导和管道药物，最近的产品认证，最近的产业活动，型材主要/利基全球以及区域市场参与者。
The report provides annual sales estimates and projections for Herpes Simplex Virus treatment for the years 2009 through 2017 for the following geographic markets - US, Europe, and Rest of World.
该报告提供了多年的单纯疱疹病毒治疗的年销售额估计和预测2009年到2017年以下的地域市场 - 美国，欧洲和世界其它地区。
For more details about this comprehensive market research report, please visit –
对于这种全面的市场调研报告的更多细节，请访问 -
http://www.strategyr.com/Herpes_Simplex_Virus_Treatment_Market_Report.asp
http://www.strategyr.com/Herpes_Simplex_Virus_Treatment_Market_Report.asp
